nasdaq:kura
|
6409368
|
Apr 14th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
176.00
|
Open
|
|
Apr 13th, 2024 11:16PM
|
Apr 14th, 2024 11:14AM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 13th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
176.00
|
Open
|
|
Apr 12th, 2024 11:07PM
|
Apr 13th, 2024 11:41AM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 12th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
176.00
|
Open
|
|
Apr 11th, 2024 11:12PM
|
Apr 12th, 2024 08:37AM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 11th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
176.00
|
Open
|
|
Apr 10th, 2024 11:45PM
|
Apr 11th, 2024 11:22AM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 10th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
176.00
|
Open
|
|
Apr 9th, 2024 11:15PM
|
Apr 10th, 2024 05:30PM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 9th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
175.00
|
Open
|
|
Apr 8th, 2024 11:26PM
|
Apr 9th, 2024 10:11AM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 8th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
175.00
|
Open
|
|
Apr 7th, 2024 11:51PM
|
Apr 8th, 2024 07:08PM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 7th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
175.00
|
Open
|
|
Apr 6th, 2024 11:21PM
|
Apr 6th, 2024 11:21PM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 6th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
175.00
|
Open
|
|
Apr 5th, 2024 11:22PM
|
Apr 5th, 2024 11:22PM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kura
|
6409368
|
Apr 5th, 2024 12:00AM
|
Kura Oncology, Inc.
|
16K
|
175.00
|
Open
|
|
Apr 4th, 2024 11:49PM
|
Apr 4th, 2024 11:49PM
|
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
For additional information, please visit Kura’s website at www.kuraoncology.com.
|
Open
|
Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
|
Open
|
12730 High Bluff Dr
|
San Diego
|
California
|
US
|
92130
|
|
Kura Oncology
|
Health Care
|
Pharmaceuticals & Biotechnology
|